GovernmentExecutive.com

An internal FDA survey that has just come to light provides more fodder for critics who say the agency lacks the capacity to adequately manage the drug approval and monitoring process. Two-thirds of FDA scientists, the survey found, said they were not at all confident or only somewhat confident that the agency properly checks up on the safety of prescription drugs once they're on the market. And more than a third expressed some doubts about the agency's process for initially approving drugs.